Clinical trials: Myocardial Inflammation
Coronary Heart Disease
Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)
The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacokinetics and pharmacodynamics of single and…
- Trial name
- NCT00568594
- Testing
- APL180
- Where
- 11 sites in United States, Belgium and 5 more
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Novartis
Coronary Disease, Heart Valve Diseases
CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)
Over 500,000 patients undergo cardiac surgery with CPB in the United States annually. Although mortality rates have decreased with advances in perioperative care, many patients are affected by postoperative organ dysfunction.
- Trial name
- NCT00107666
- Testing
- CTI-01 (ethyl pyruvate)
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Critical Therapeutics
Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction
Impact of Cardiac Rehabilitation Programs on Left Ventricular Remodeling After Acute Myocardial Infarction - the REHAB Trial
The aim of REHAB trial is to investigate the impact of early mobilization after AMI in reducing left ventricular remodeling, as assessed by cardiac magnetic resonance imaging.
- Conditions
- Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction, Systemic Inflammation, Ventricular Remodeling
- Trial name
- NCT04161378
- Testing
- Cardiac imaging, Laboratory analysis
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Coronary Heart Disease
A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention
Study of SB-681323 (a novel p38 MAPkinase inhibitor) in subjects with documented coronary heart disease (CHD) undergoing elective percutaneous coronary intervention (PCI).
- Trial name
- NCT00291902
- Testing
- SB-681323
- Where
- 7 sites in Denmark, Poland
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Acute Myocardial Infarction, Heart Failure
Inflammation-mediated Coronary Plaque Vulnerability, Myocardial Viability and Ventricular Remodeling
VIABILITY study aims to investigate the link between systemic inflammation, pancoronary plaque vulnerability (referring to the plaque vulnerability within the entire coronary tree), myocardial viability and ventricular remodeling…
- Trial name
- VIABILITY (NCT03830944)
- Testing
- Blood sampling, transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance
- Where
- Romania
- Volunteers
- 150 people
- Sponsor
- Cardio Med Medical Center
Myocarditis
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
The main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mRNA-1273 (SPIKEVAX) COVID-19 vaccine.
- Trial name
- NCT06189053
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- ModernaTX, Inc.
Cancer
Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells
A retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells
- Trial name
- NCT03644498
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 1,056 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease
The primary purpose of this study is to assess the safety and tolerability of E5555 in subjects with coronary artery disease.
- Trial name
- NCT00312052
- Testing
- E5555
- Where
- 2 sites in United States
- Volunteers
- 720 people
- Sponsor
- Eisai Inc.
Hypertension, Coronary Arteriosclerosis
Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism
Effects of AT1 receptor antagonist telmisartan on the primary endpoint inflammatory parameters in patients with coronary artery disease (CAD). Secondary endpoints are alterations in clinical course and blood pressure
- Trial name
- NCT00274144
- Testing
- telmisartan 40 mg
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Acute ST Segment Elevation Myocardial Infarction
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial…
- Trial name
- NCT04463251
- Testing
- RPH-104 80 mg
- Where
- 11 sites in United States, Russia
- Volunteers
- 102 people
- Sponsor
- R-Pharm Overseas, Inc.
Acute Coronary Syndrome
Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.
- Trial name
- NCT00552188
- Testing
- VIA-2291
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Myocardial Infarction, Glycation End Products, Advanced
Role of Glycation and Inflammation in Acute Ischemic Heart Disease
This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting…
- Conditions
- Myocardial Infarction, Glycation End Products, Advanced, Inflammation, Heart Injuries
- Trial name
- AGLIANICO (NCT05112731)
- Testing
- BAFF and MGO
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- GEK Srl
Atrial Fibrillation, Atrial Inflammation
Inflammation, Fibrosis and Risk of Recurrence After Atrial Fibrillation Ablation
FIBRO-RISK study aims to investigate the impact of inflammatory-mediated myocardial fibrosis on the risk of recurrence after successful ablation of atrial fibrillation.
- Trial name
- FIBRO-RISK (NCT03757741)
- Testing
- Cardiac imaging tests, Venous blood samle collection
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Coronary Stenosis, Periodontal Diseases
Periodontal Disease, Inflammation and Acute Coronary Syndromes
Recent studies have shown that the systemic inflammation caused by periodontal disease (PD) can determine important changes in the coronary arteries, favoring atherosclerosis progression and development of acute coronary…
- Conditions
- Coronary Stenosis, Periodontal Diseases, Acute Coronary Syndrome, Non-ST Elevation Myocardial Infarction
- Trial name
- ATHERODENT (NCT03395041)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 149 people
- Sponsor
- Cardio Med Medical Center
Coronary Artery Disease, Systemic Inflammatory Response
CCTA Coronary Hemodynamics, Systemic Inflammation and Vulnerable Plaques (COHESIVE)
Although there are numerous studies that have demonstrated the impact of systemic inflammation on coronary plaque vulnerability, there are few literature data regarding the influence of coronary plaque localization within the…
- Conditions
- Coronary Artery Disease, Systemic Inflammatory Response, Chronic Coronary Syndrome, Atherosclerosis
- Trial name
- COHESIVE (NCT05488249)
- Testing
- Cardiac imaging tests, Venous blood sample collection
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Acute Coronary Syndromes, Coronary Arterial Disease (CAD)
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA.
- Conditions
- Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
- Trial name
- FORTIFY (NCT06927739)
- Testing
- Orticumab
- Where
- 41 sites in United States, Czechia and 7 more
- Volunteers
- 240 people
- Sponsor
- Abcentra
Cardiac Arrest, Renal Failure
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
To evaluate the effect of automated recording on frequency of recorded scores, number of automated notifications and serious events.
- Conditions
- Cardiac Arrest, Renal Failure, Respiration Failure, Myocardial Infarction
- Trial name
- NCT02973243
- Testing
- Automatic RR Measurement
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- Philips Healthcare
Myocarditis, Pericarditis
ACAM2000® Myopericarditis Registry
The purpose of this registry is to study the natural history of vaccination-related myocarditis and pericarditis and to assess possible risk factors for these conditions.
- Trial name
- NCT01395082
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Acute Coronary Syndrome
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome
This is a multi-center, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of E5555 in subjects with Acute coronary syndrome (ACS).
- Trial name
- NCT00548587
- Testing
- E5555
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Eisai Inc.